This invention relates to compounds that are agonists of the muscarinic M1 receptor and/or M4 receptor and which are useful in the treatment of muscarinic M1/M4 receptor mediated diseases. Also provided are pharmaceutical compositions containing the compounds and the therapeutic uses of the compounds. Compounds include those according to formula (1a):
or a salt thereof, wherein p, q, r, s, Q, R3 and R4 are as defined herein.
This invention relates to compounds that are agonists of the muscarinic M1 receptor and/or M4 receptor and which are useful in the treatment of muscarinic M1/M4 receptor mediated diseases. Also provided are pharmaceutical compositions containing the compounds and the therapeutic uses of the compounds. Compounds include those according to formula (1a)
or a salt thereof, wherein p, q, r, s, Q, R3 and R4 are as defined herein.
BICYCLIC HETEROARYL AMINE COMPOUNDS AS PI3K INHIBITORS
申请人:Bristol-Myers Squibb Company
公开号:EP3209664B1
公开(公告)日:2020-06-03
EP3331869B1
申请人:——
公开号:EP3331869B1
公开(公告)日:2020-12-23
Muscarinic Agonists
申请人:Heptares Therapeutics Limited
公开号:US20170037025A1
公开(公告)日:2017-02-09
This invention relates to compounds that are agonists of the muscarinic M
1
receptor and/or M
4
receptor and which are useful in the treatment of muscarinic M
1
/M
4
receptor mediated diseases. Also provided are pharmaceutical compositions containing the compounds and the therapeutic uses of the compounds. Compounds include those according to formula (1a)
or a salt thereof, wherein p, q, r, s, Q, R
3
and R
4
are as defined herein.